
EFSA Seeks Feedback on Overhaul of Weight of Evidence and Biological Relevance Guidance
EFSA launches consultation on updating its Weight of Evidence and Biological Relevance guidance, aiming to streamline chemical risk assessment practices.


In a significant step towards addressing public health concerns, the European Union, through the European Commission and its Scientific Committee on Health, Environmental and Emerging Risks (SCHEER), has opened a public consultation on the preliminary update of the SCHEER guidelines. This initiative focuses on the benefit-risk assessment of the presence of phthalates in certain medical devices, particularly those identified as carcinogenic, mutagenic, toxic to reproduction (CMR), or having endocrine-disrupting (ED) properties.
This consultation is crucial for the advancement of safer medical devices and invites input from all relevant stakeholders, including manufacturers, notified bodies, regulatory entities, and the general public.
The updated guidelines serve a vital role in ensuring the safety and efficacy of medical devices that contain phthalates with CMR or ED properties. Key aspects of the guidelines include:
The initiative underscores the EU's commitment to public health and safety by regulating the use of potentially harmful substances in medical devices. By revising the SCHEER guidelines, the European Commission aims to reflect the latest scientific evidence and promote the development and use of safer alternatives.
Stakeholders are encouraged to provide feedback on the preliminary guidelines by submitting written comments through the designated electronic template by the specified deadline. This process allows for a comprehensive review of the scientific basis of the guidelines and identification of areas requiring further investigation.
SCHEER has reiterated the importance of manufacturers generating high-quality data on alternatives to CMR/ED phthalates in medical devices. Such data are crucial for informed decision-making and the development of safer medical products.
The feedback obtained from this consultation will play a pivotal role in shaping the final guidelines, ensuring they effectively address the risks associated with phthalates in medical devices. The European Commission's proactive approach, through SCHEER, highlights the ongoing efforts to enhance public health protections within the EU.
This public consultation represents a collaborative effort to refine regulatory standards and promote the safety of medical devices across Europe. Stakeholders are urged to participate actively in this critical consultation process.
Foresight continuously tracks 1000s of sources and maps updates to your portfolio:




EFSA launches consultation on updating its Weight of Evidence and Biological Relevance guidance, aiming to streamline chemical risk assessment practices.

The Netherlands refines its list of potential ZZS chemicals to better align with EU assessments, boosting early detection and regulatory foresight.

Eurostat’s new occupational disease manual impacts EU chemical regulations. Discover how standardised data reporting will shape compliance and safety.
Subscribe to Foresight Weekly and get the latest insights on regulatory changes affecting chemical compliance.
Free forever. Unsubscribe anytime.
Read by professionals at